JPH03206036A - Agent for lowering hepatotoxicity and suppressing dysplasia of hepatocyte - Google Patents
Agent for lowering hepatotoxicity and suppressing dysplasia of hepatocyteInfo
- Publication number
- JPH03206036A JPH03206036A JP34181089A JP34181089A JPH03206036A JP H03206036 A JPH03206036 A JP H03206036A JP 34181089 A JP34181089 A JP 34181089A JP 34181089 A JP34181089 A JP 34181089A JP H03206036 A JPH03206036 A JP H03206036A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- hepatotoxicity
- dysplasia
- reducing
- oxygermylpropionic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010019851 Hepatotoxicity Diseases 0.000 title claims abstract description 10
- 231100000304 hepatotoxicity Toxicity 0.000 title claims abstract description 9
- 230000007686 hepatotoxicity Effects 0.000 title claims abstract description 9
- 206010058314 Dysplasia Diseases 0.000 title claims abstract 8
- 210000003494 hepatocyte Anatomy 0.000 title abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims abstract 4
- 229930182555 Penicillin Natural products 0.000 claims abstract 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract 2
- 230000000202 analgesic effect Effects 0.000 claims abstract 2
- 229960000905 indomethacin Drugs 0.000 claims abstract 2
- 229960000318 kanamycin Drugs 0.000 claims abstract 2
- 229930027917 kanamycin Natural products 0.000 claims abstract 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims abstract 2
- 229930182823 kanamycin A Natural products 0.000 claims abstract 2
- 229940049954 penicillin Drugs 0.000 claims abstract 2
- 229910052697 platinum Inorganic materials 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 229960005322 streptomycin Drugs 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 231100000334 hepatotoxic Toxicity 0.000 claims 4
- 230000003082 hepatotoxic effect Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 150000002484 inorganic compounds Chemical class 0.000 claims 1
- 229910010272 inorganic material Inorganic materials 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 230000003327 cancerostatic effect Effects 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012190 activator Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
PURPOSE:To obtain a safely applicable agent for lowering hepatotoxicity and suppressing dysplasia of hepatocyte by using 3-oxygermulpropionic acid singly or in combination with an action-promoting carrier. CONSTITUTION:The compound of formula (n is integer of >=1) is used singly or in combination with an action-promoting carrier such as hyroxypropyl cellulose. The amounts of the compound of formula and hydroxypropyl cellulose are 0.05-5wt.% and 0.2-50wt.%, respectively. It is administered by compounding with a remedying drug strong hepatotoxicity, e.g. indomethacin analgesic, antibiotics such as streptomycin, kanamycin or penicillin, carcinostatic agent such as 5-FU or platinum complex salt, etc.
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は次式、
（９ ＧｅＣＨ２ＣＨ２ＣＯＯＨ） ． ０１．５ｎ（
式中ｎは】又はそれ以上の整数を意味する）にて示され
る化合物あるいは該化合物０．０５〜５重量％に対して
活性化剤としてのヒドロキシプロピルセルロース０．２
〜５０重量％の組成形態を有する作用活性化組成物から
なる肝毒性軽減並びに肝細胞興形成抑制剤に係る．
なお、本発明に使用される化合物は白色針状結晶を有し
、比重（密度＞２．２３、溶解度（水）１．．５７（２
０度Ｃ〉、融点約２３０度Ｃ（分解）の物理化学的性質
を有するものである．（従来の技術）DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to the following formula: (9 GeCH2CH2COOH) . 01.5n(
0.2% of hydroxypropylcellulose as an activator per 0.05 to 5% by weight of the compound represented by the following formula or an integer greater than or equal to
The present invention relates to an agent for reducing hepatotoxicity and inhibiting hepatocyte formation, comprising an action-activating composition having a composition of ~50% by weight. The compound used in the present invention has white needle-like crystals, specific gravity (density > 2.23, solubility (water) 1.57 (2
It has physicochemical properties with a melting point of about 230 degrees C (decomposition). (Conventional technology)
Claims (6)
ｎは１又はそれ以上の整数を意味する）にて示される３
−オキシゲルミルプロピオン酸単独あるいは３−オキシ
ゲルミルプロピオン酸と作用活性化担体からなる肝毒性
軽減並びに肝細胞異形成抑制剤。(1) 3 shown by the formula (■GeCH2CH2COOH)_n01.5n (in the formula, n means an integer of 1 or more)
- An agent for reducing hepatotoxicity and inhibiting hepatocellular dysplasia consisting of oxygermylpropionic acid alone or 3-oxygermylpropionic acid and an active carrier.
であり、３−オキシゲルミルプロピオン酸０．００５〜
５重量％に対してヒドロキシプロピルセルロースを０．
００５〜５０重量％の組成物形態を有する肝毒性軽減並
びに肝細胞異形成抑制剤。(2) The action-activating carrier is hydroxypropylcellulose, and 3-oxygermylpropionic acid is 0.005~
0.5% by weight of hydroxypropylcellulose.
A hepatotoxicity-reducing agent and hepatocellular dysplasia inhibitor having a composition form of 005 to 50% by weight.
痛剤、ストレプトマイシン系、カナマイシン系、セフア
ロスポリン系、ペニシリン系、マイトマイシン系抗生剤
、あるいは５−ＦＵ系、白金錯塩系抗癌剤であり、請求
項１記載の３−オキシゲルミルプロピオン酸あるいは３
−オキシゲルミルプロピオン酸と活性化担体による組成
物との配合形態を有する肝毒性軽減並びに肝細胞異形成
抑制剤。(3) The highly hepatotoxic therapeutic drug is an indomethacin-based analgesic, a streptomycin-based, kanamycin-based, cephalosporin-based, penicillin-based, mitomycin-based antibiotic, or a 5-FU-based or platinum complex salt-based anticancer drug, as claimed in claim 1. 3-oxygermylpropionic acid or 3 as described
- An agent for reducing hepatotoxicity and inhibiting hepatocellular dysplasia, which has a composition comprising oxygermylpropionic acid and an activated carrier.
系物質である請求項１〜３記載の肝毒性軽減並びに肝細
胞異形成抑制剤。(4) The agent for reducing hepatotoxicity and inhibiting hepatocellular dysplasia according to claims 1 to 3, wherein the highly hepatotoxic substance is an organic or inorganic compound or a biological substance.
ール系物質であり、肝毒性の強い生物系物質がＡ型肝炎
、Ｂ型肝炎、非Ａ非Ｂ型肝炎ウィルスである請求項１〜
４記載の肝毒性軽減並びに肝細胞異形成抑制剤。(5) Claims 1 to 5, wherein the highly hepatotoxic compound is a chlorinated organic solvent alcohol-based substance, and the highly hepatotoxic biological substance is hepatitis A, hepatitis B, or non-A, non-B hepatitis virus.
4. The agent for reducing hepatotoxicity and suppressing hepatocellular dysplasia according to 4.
毒性軽減並びに肝細胞異形成抑制剤。(6) The agent for reducing hepatotoxicity and inhibiting hepatocellular dysplasia according to claims (1) to (5), which is in the form of a tablet.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP34181089A JPH03206036A (en) | 1989-12-29 | 1989-12-29 | Agent for lowering hepatotoxicity and suppressing dysplasia of hepatocyte |
| DE69017870T DE69017870T2 (en) | 1989-12-29 | 1990-12-28 | Pharmaceutical preparations containing 3-oxygermylpropionic acid polymers to inhibit cell degeneration. |
| EP90314407A EP0435693B1 (en) | 1989-12-29 | 1990-12-28 | Pharmaceutical compositions containing 3-oxygermylpropionic acid polymers for inhibiting the degeneration of cells |
| ES90314407T ES2069711T3 (en) | 1989-12-29 | 1990-12-28 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-OXYGERMYLPROPIONIC ACID POLYMERS TO INHIBIT CELL DEGENERATION. |
| US07/881,318 US5240700A (en) | 1989-12-29 | 1992-05-07 | Pharmaceutical composition comprising a medicament and 3-oxygermylpropionic acid |
| HK114295A HK114295A (en) | 1989-12-29 | 1995-07-13 | Pharmaceutical compositions containing 3-oxygermyl-propionic acid polymers for inhibiting the degeneration of cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP34181089A JPH03206036A (en) | 1989-12-29 | 1989-12-29 | Agent for lowering hepatotoxicity and suppressing dysplasia of hepatocyte |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03206036A true JPH03206036A (en) | 1991-09-09 |
Family
ID=18348937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP34181089A Pending JPH03206036A (en) | 1989-12-29 | 1989-12-29 | Agent for lowering hepatotoxicity and suppressing dysplasia of hepatocyte |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03206036A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113710679A (en) * | 2019-10-24 | 2021-11-26 | 株式会社浅井锗研究所 | Novel organogermanium compounds |
-
1989
- 1989-12-29 JP JP34181089A patent/JPH03206036A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113710679A (en) * | 2019-10-24 | 2021-11-26 | 株式会社浅井锗研究所 | Novel organogermanium compounds |
| US11981693B2 (en) | 2019-10-24 | 2024-05-14 | Asai Germanium Research Institute Co., Ltd. | Organogermanium compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2217145C2 (en) | Heteroarylalkenyl derivatives of cyclopentaneheptan(en)oic acid | |
| RU2223272C2 (en) | Derivative of 2-aryl-8-oxodihydropurine, method for its preparing, pharmaceutical composition and agent comprising thereof, intermediate compound | |
| CA1100875A (en) | Tetracycline antibiotic compositions | |
| CA2310141A1 (en) | Use of sulphinyl benzhydryl derivatives for treating drug-induced sleepiness | |
| DE69333723D1 (en) | PHARMACEUTICAL PREPARATION BASED ON RHAMNOLIPIDE AGAINST DERMATOLOGICAL DISEASES | |
| JPH04360833A (en) | Pharmaceutical containing 1,4-dihydropyridine derivative | |
| JPH03206036A (en) | Agent for lowering hepatotoxicity and suppressing dysplasia of hepatocyte | |
| AU2003235156B2 (en) | Solid dispersion composition | |
| RU97104483A (en) | SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT | |
| KR920019350A (en) | Pharmaceutical Compositions for Autoimmune Disease Therapy | |
| JPS63253022A (en) | Baclofen pharmaceutical for external use | |
| KR900009677A (en) | New compounds | |
| HU177873B (en) | Further developped process for preparing an aequous solution containing a complex of n-/3-chloro-4-/4-chloro-phenoxy/-phenyl/-2-hydroxy-3,5-diiodo-benzamide with polyvinyl-pyrrolidone | |
| RU94046463A (en) | Antiandrogenic compound, drug precursor, pharmaceutical compositions, process for medical treatment or prevention of diseases | |
| RU2205829C2 (en) | Substituted derivative of cyclobutylamine, antibacterial agent and pharmaceutical composition based on thereof | |
| CA2256391A1 (en) | Anticoagulant peptidyl-arginine aldehyde derivatives | |
| JP4130700B2 (en) | Antitumor agent-containing composition | |
| JPH0459730A (en) | Cephem-based antibiotic-containing lyophilized preparation | |
| CO5170463A1 (en) | POLYMORPH FORMS OF AN AZOBICICLO CITRATE [2,2,2] OCTAN-3-AMINA AND ITS PHARMACEUTICAL COMPOSITIONS | |
| KR950702528A (en) | N ^ G-monomethyl-L (L) -arginine hydrogen chloride derivatives and their use in the treatment of septic shock, (N ^ G-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK) | |
| JPS61137818A (en) | Antitumor agent | |
| EP0323762B1 (en) | Antitussive compositions and their preparation | |
| US3887706A (en) | N6-(3-Chlorobuten-2-yl)-adenosines as anti-inflammatory agents | |
| CA2520813A1 (en) | Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists | |
| JPS5942318A (en) | Therapeutical composition, manufacture and use |